Utility of DWI-MRI and histopathological evaluation on early response of HCC with molecular targeting therapy

Utility of DWI-MRI and histopathological evaluation on early response of HCC with molecular targeting therapy - Utility of DWI-MRI and histopathological evaluation on early response of HCC with molecular targeting therapy

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000045714

Enrollment

Registered

2021-10-11

Start date

2020-10-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Equal or more than 20 years old 2. Histopathologic diagnosed as HCC 3. Nonresectable HCC 4. Patients with fully informed consent

Exclusion criteria

Exclusion criteria: 1. Allergy with iodine contrast media 2. eGFR is less than 40ml/min 3. Child-Pugh is B and C 4. Not suitable for the study due to researcher's decision

Design outcomes

Primary

Measure	Time frame
Relationship between DWI-MRI, histopathologic evaluation, and exosome and radiological response on RECIST 1.1	—

Countries

Japan

Contacts

Public ContactKatsutoshi Sugimoto

Tokyo Medical University Dept. of Gastroenterology and Hepatology

sugimoto@tokyo-med.ac.jp03-3342-6111

Outcome results